SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors aggressively position ahead of its earnings report, with community sentiment split between high expectations for a major hyperscaler contract and fears of a sell-off if the news fails to materialize. Traders are closely monitoring heavy options activity and sector-wide momentum in AI infrastructure, with many debating whether to hold through potential volatility or lock in profits from the stock's recent gains.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is experiencing intense volatility as investors speculate on a potential short squeeze and a rumored partnership with OpenAI ahead of earnings. Community sentiment remains deeply polarized, with many traders frustrated by consistent intraday sell-offs while others aggressively defend their positions based on the CEO's recent large-scale share purchases.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community speculation as investors position themselves ahead of upcoming earnings, with many anticipating that a shift toward improved unit economics and strategic acquisitions will trigger a significant breakout. Discussion is dominated by bullish sentiment regarding the company's long-term path to profitability and potential for a short squeeze, while traders weigh the impact of shifting mortgage dynamics and recent operational updates.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing intense community focus ahead of its quarterly earnings release, with investors closely watching for updates on its Neutron rocket program, defense contract conversions, and revenue growth. Sentiment remains bullish, as market participants look past recent volatility, citing the company's expanding backlog and position as a key strategic partner in the growing space defense and satellite infrastructure sectors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge in social media activity as investors position themselves ahead of the upcoming earnings release, debating whether the stock will trigger a major short squeeze given its high short interest and institutional accumulation. The community remains sharply divided, with bulls pointing to strong AI growth narratives and potential partnerships, while bears continue to raise concerns regarding the company's path to profitability and recent valuation run-up.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing extreme volatility as investors weigh massive revenue growth and hyperscaler tailwinds against concerns over heavy debt, rising capital expenditures, and significant insider selling ahead of the earnings report. The community remains sharply divided, with bulls betting on a breakout fueled by AI demand, while bears anticipate a post-earnings sell-off due to the company's historical volatility and high burn rate.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics is facing extreme market volatility as investors weigh the significant risk of a negative regulatory outcome against the potential for an FDA approval catalyst. The community is heavily focused on the company's precarious cash position and the possibility of dilutive financing, with many debating whether the stock is a high-risk squeeze opportunity or headed for further downside.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently the focus of investor attention as it faces high-stakes earnings after a round of workforce reductions and ongoing debate surrounding the Clarity Act. Market participants are actively weighing concerns about the company's cost structure and competitive positioning against bullish sentiment regarding institutional adoption and its evolving role in financial infrastructure.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a sharp sell-off following quarterly earnings that investors are viewing as a 'sell the news' event despite reported growth. The community is actively debating whether the stock is a deep-value buying opportunity or if the current momentum suggests a continued slide, with many traders questioning why the market reaction has been so severe given the company's raised guidance.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors weigh potential impacts from the emerging prediction market sector and upcoming first-quarter earnings, leading to intense community debate over long-term growth prospects. Discussions are dominated by speculation on whether these new markets will cannibalize traditional sports betting revenue or serve as an additive growth driver for the platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teladoc Health (NYSE:TDOC) Price Target Raised to $7.00 at Citigroup

Citigroup lifted their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a "neutral" rating in a report on Tuesday...

TDOC Q1 Earnings Miss, Revenues Down Y/Y on BetterHelp Weakness

Teladoc Health posts a y/y narrower Q1 loss and beats revenue estimates as international growth and cost cuts offset BetterHelp weakness and subscription declines.

Teladoc Health Q1 Earnings Call Highlights

Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company's guidance for both revenue and Adjusted...

Teladoc Health (NYSE:TDOC) Stock Price Up 7.7%  - Here's Why

Teladoc Health (NYSE:TDOC) Trading Up 7.7% - What's Next...

Teladoc Health Target of Unusually Large Options Trading (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) was the recipient of some unusual options trading on Friday. Traders acquired 28,675 call options on the company. This represents an increase of 102% compared to the average volume of 14,214 call options...

HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

<ul class="summary-bullets"><li>Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding.</li><li>The 503B Bulk List features drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines.</li><li>The agency said there is insufficient evidence to justify broader access to compounded versions.</li></ul>The U.S. Food and Drug Administration, on Thursday, issued a proposal to exclude several popular weight-loss and diabetes drugs from its 503B bulks list, limiting how they can be compounded by outsourcing facilities.Semaglutide, the key ingredient in Novo Nordisk’s (NVO) Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly (LLY) as Zepbound and Mounjaro, would be excluded from bulk compounding. The Liraglutide.<h2 class="st-heading-2">FDA Sees No Clinical Need For Compounding Weight Loss Drugs</h2>The 503B Bulk List is an FDA-approved list of drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines. In most cases, facilities can only compound drugs from bulk ingredients if they appear on this list or if the drug is officially in shortage.After reviewing available data, the FDA said it found no clear clinical need to allow compounding of these drugs from raw ingredients. The agency added that its decision is based on patient safety and medical necessity, noting that there is insufficient evidence to justify broader access to compounded versions.“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary.<h2 class="st-heading-2">FDA’s Concerns With Compounded Weight Loss Drugs</h2>The agency has been vocal about its issue with compounded weight-loss drugs. In February, the FDA said it intends to tighten rules around GLP-1 ingredients used in compounded medicines, citing concerns about quality, safety, and possible legal issues. Compounded drugs are not reviewed or approved by the FDA.The agency <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-hours-fda-chief-warns-of-swift-action-on-copycat-drugs-after-novo-semaglutide-knockoff-launch/cZbnUBER4nQ">added</a> that compounded GLP-1 drugs should be used only when a patient’s needs cannot be met by an approved treatment. It also flagged risks such as improper storage, dosing mistakes, and counterfeit or misleadingly marketed products.Earlier this year, Novo Nordisk sued Hims &amp; Hers (HIMS) for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug. However, the two companies later reconciled,<a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">&nbsp;teaming</a> up to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices on the telehealth platform.Meanwhile, shares of LLY and NVO gained 9% and 5%, respectively, while HIMS edged 0.5% lower and Teladoc Health (TDOC) fell 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-up-earnings-mounjaro-zepbound/cZBMJq7Re4X">LLY Stock Up 7% Pre-Market As Mounjaro, Zepbound Sales Smash Expectations – Retail Bets On Run Toward $1,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Moves To Block Compounded Versions Of Popular Weight-Loss Drugs – NVO, LLY Stocks Gain

The FDA issued a proposal to exclude several popular weight-loss and diabetes drugs from being compounded by outsourcing facilities.

Equity

Teladoc Health (NYSE:TDOC) Shares Gap Down on Disappointing Earnings

Teladoc Health (NYSE:TDOC) Shares Gap Down After Earnings Miss...

Teladoc Health (NYSE:TDOC) Issues Earnings Results, Misses Estimates By $0.02 EPS

Teladoc Health (NYSE:TDOC - Get Free Report) issued its earnings results on Wednesday. The health services provider reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by...

Here's What Key Metrics Tell Us About Teladoc (TDOC) Q1 Earnings

While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Current Price	$6.97
Prev Close	$6.80
Open	$6.85
Dividend Yield	0.00%
50-Day Moving Average	$5.54
Beta	1.55
Avg. Volume	4.67M
PE Ratio	-7.06

52-Week High	$9.77
52-Week Low	$4.40
Market Capitalization	$1.23B
EPS (Annual)	-$1.14
Price to Book	0.92
Revenue Per Employee	$451,781.61

TDOC
Teladoc Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TDOC News

TDOCTeladoc Health Inc